Arecor Therapeutics plc
AREC.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | £2 | £3 | £2 | £3 |
| % Growth | -34.5% | 53.3% | -31.3% | – |
| Cost of Goods Sold | £2 | £4 | -£0 | £0 |
| Gross Profit | £0 | -£1 | £2 | £3 |
| % Margin | 16.4% | -22% | 111% | 110.4% |
| R&D Expenses | £1 | £1 | £2 | £3 |
| G&A Expenses | £0 | £0 | £0 | £0 |
| SG&A Expenses | £2 | £1 | £3 | £5 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | £0 | £3 | £0 | -£0 |
| Operating Expenses | £3 | £5 | £5 | £7 |
| Operating Income | -£3 | -£3 | -£8 | -£4 |
| % Margin | -152.9% | -91.7% | -395.7% | -124.3% |
| Other Income/Exp. Net | £1 | -£3 | £3 | -£0 |
| Pre-Tax Income | -£3 | -£6 | -£5 | -£4 |
| Tax Expense | -£0 | -£0 | -£0 | -£0 |
| Net Income | -£3 | -£6 | -£5 | -£4 |
| % Margin | -125.2% | -183% | -232.6% | -138.6% |
| EPS | -0.066 | -0.15 | -0.15 | -0.13 |
| % Growth | 55.7% | 0% | -15.4% | – |
| EPS Diluted | -0.066 | -0.15 | -0.15 | -0.13 |
| Weighted Avg Shares Out | 38 | 38 | 31 | 31 |
| Weighted Avg Shares Out Dil | 38 | 38 | 31 | 31 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£2 | -£6 | -£5 | -£4 |
| % Margin | -120.9% | -183% | -228.2% | -140.2% |